Sponsor
- Home
- Your Messages
-
Smartest Doc
Daily Quiz CompetitionTest your clinical knowledge against other physicians in the USA by taking our FREE daily quiz!
New! PHYSICIAN REVIEW
Thousands of questions to assess your knowledge and aid exam prep!
- Physician Jobs (363)
- More
- Other Specialty
Efficacy and safety of ribosome-component immune modulator for preventing recurrent respiratory infections in socialized children Allergy and Asthma Proceedings, 05/09/2012
Fiocchi A et al. – No statistically significant between–treatment differences were observed for other end points. Both treatments were similarly well tolerated. Six–month treatment with ribosome–component immune modulator (RCIM) effectively prevented the 12–month risk of recurrent respiratory infections (RRIs) in children <5years old and with five or less RRIs in the preceding year.
Register now to view all the MDLinx contents (FREE)!
- Stay current on the latest literature, research and clinical news
- Get special communications and offers from MDLinx and our sponsors
- Receive invitations to paid market research
Login
Sponsor
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close
Sponsor